Recent Updates
Recently added Catalysts
NERV Positive Sentiment

Minerva Neurosciences to Participate in The Citizens Life Sciences Conference

Key Takeaway: Minerva Neurosciences, Inc. will participate in The Citizens Life Sciences Conference on March 10-11, 2026, in Miami, FL. CEO Remy Luthringer will represent the company, which is focused on CNS disorder therapies. A replay of the presentation will be accessible for 90 days post-event. The company is also initiating a Phase 3 trial for its drug roluperidone.
Price reaction · baseline $6.86 (2026-03-03 close) · hit pre-market · clean, no other NERV news in the window
day 0 close
-0.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Minerva Neurosciences is actively participating in a significant conference.
  • The company is focused on developing therapies for CNS disorders.
  • A Phase 3 trial for roluperidone is being initiated, indicating progress.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+355%
120-day peak, hindsight
Typical move
29.3%
average across 2 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
MIN-117
Phase 2 · Major Depressive Disorder

Full Press Release Details

BURLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in The Citizens Life Sciences Conference being held March 10-11, 2026 in Miami, FL.
The Citizens Life Sciences Conference
Format: Company presentation
Day/Time: Tuesday, March 10 at 9:35 AM ET
Webcast: https://event.summitcast.com/view/BuMiPNPtyHKimMF6k4AFMd/SKrutqyvQVtnaKJDseE6uU
If you are interested in meeting with the Minerva team during the conference, please reach out to your Citizens Bank representative.
A replay of the presentation will be available on the Company's Investors & MediaEvents and Presentationswebpage for ninety days following the event.

About Minerva Neurosciences

MinervaNeurosciences, Inc.is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is initiating a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’swebsite.

Contacts:Investor inquiries:

Frederick AhlholmChief Financial OfficerMinerva Neurosciences, Inc.FAhlholm@minervaneurosciences.com

Corey Davis, Ph.D.LifeSci Advisors, LLC212-915-2577cdavis@lifesciadvisors.com

Frequently Asked Questions

When is The Citizens Life Sciences Conference?

The Citizens Life Sciences Conference will be held on March 10-11, 2026.

Who will represent Minerva Neurosciences at the conference?

Remy Luthringer, PhD, will represent Minerva Neurosciences.

What is Minerva Neurosciences focused on developing?

Minerva Neurosciences focuses on therapies for central nervous system disorders.

What trial is Minerva initiating?

Minerva is initiating a confirmatory Phase 3 trial with roluperidone.

Last updated: Mar 4, 2026